Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry.
Felix CM, Fam JM, Diletti R, Ishibashi Y, Karanasos A, Everaert BR, van Mieghem NM, Daemen J, de Jaegere PP, Zijlstra F, Regar ES, Onuma Y, van Geuns RJ. Felix CM, et al. JACC Cardiovasc Interv. 2016 Aug 22;9(16):1652-63. doi: 10.1016/j.jcin.2016.04.035. Epub 2016 Jul 27. JACC Cardiovasc Interv. 2016. PMID: 27476094 Free article.
Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction: a propensity-matched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first study.
Fam JM, Felix C, van Geuns RJ, Onuma Y, Van Mieghem NM, Karanasos A, van der Sijde J, De Paolis M, Regar E, Valgimigli M, Daemen J, de Jaegere P, Zijlstra F, Diletti R. Fam JM, et al. EuroIntervention. 2016 May 17;12(1):30-7. doi: 10.4244/EIJV12I1A6. EuroIntervention. 2016. PMID: 27173859 Free article.
Differential thrombotic prolapse burden in either bioresorbable vascular scaffolds or metallic stents implanted during acute myocardial infarction: The snowshoe effect: Insights from the maximal footprint analysis.
Diletti R, van der Sijde J, Karanasos A, Fam JM, Felix C, van Mieghem NM, Regar E, Rapoza R, Zijlstra F, van Geuns RJ. Diletti R, et al. Int J Cardiol. 2016 Oct 1;220:802-8. doi: 10.1016/j.ijcard.2016.06.077. Epub 2016 Jun 23. Int J Cardiol. 2016. PMID: 27394977
Expanded clinical use of everolimus eluting bioresorbable vascular scaffolds for treatment of coronary artery disease.
Diletti R, Ishibashi Y, Felix C, Onuma Y, Nakatani S, van Mieghem NM, Regar E, Valgimigli M, de Jaegere PP, van Ditzhuijzen N, Fam JM, Ligthart JMR, Lenzen MJ, Serruys PW, Zijlstra F, Jan van Geuns R. Diletti R, et al. Catheter Cardiovasc Interv. 2017 Jul;90(1):58-69. doi: 10.1002/ccd.26832. Epub 2016 Nov 29. Catheter Cardiovasc Interv. 2017. PMID: 27896897
Everolimus-eluting bioresorbable vascular scaffolds for treatment of complex chronic total occlusions.
Fam JM, Ojeda S, Garbo R, Latib A, La Manna A, Vaquerizo B, Boukhris M, Vlachojannis GJ, van Geuns RJ, Ezhumalai B, Kawamoto H, van der Sijde J, Felix C, Pan M, Serdoz R, Boccuzzi GG, De Paolis M, Sardella G, Mancone M, Tamburino C, Smits PC, Di Mario C, Seth A, Serra A, Colombo A, Serruys P, Galassi AR, Zijlstra F, Van Mieghem NM, Diletti R. Fam JM, et al. EuroIntervention. 2017 Jun 20;13(3):355-363. doi: 10.4244/EIJ-D-16-00253. EuroIntervention. 2017. PMID: 28218604 Free article.
47 results